Global Cholesterol Management Devices Market Size, Share, Forecast Report, 2020-2027

Cholesterol is a type of lipid molecule, which is biosynthesized by all animal cells as it is an essential structural component of the cells. Cholesterol management devices are used to determine a lipoprotein profile and to measure total cholesterol content, high-density lipoprotein (HOL), low-density lipoprotein (LDL), triglycerides, and other fatty substances found in the human body. The global cholesterol management devices market is driven by increasing obese and overweight population base. According to the World Health Organization (2014), worldwide, more than 1.9 billion adults over 18 years were overweight of which over 600 million were obese. Less physical activity due to the desk-bound nature of many forms of work, changing modes of transportation, government support for the research and development, and increasing urbanization have fueled the growth of the market. However, lack of awareness among the people may slow the growth of the market.

The Global Cholesterol Management Devices Market Is Expected To Grow At A CAGR Of 8.5% During The Forecast Period (2017-2023).

Segmentation

The global cholesterol management devices market is segmented on the basis of types, application and end users. On the basis of types, the market is classified into monitors, wrist monitors, small portable instruments, meters, wireless systems, and others. On the basis of applications, the market is categorized into hypercholesterolemia, hypocholesterolemia, cholesterol testing, and others. On the basis of end users, the market is segmented into home based healthcare, hospitals, clinics, and others.
Key Players for Global Cholesterol Management Devices Market

Some of the key player in the market are Boston Scientific Corporation (US), Medtronic (US), St. Jude Medical, LLC. (Canada), Koninklijke Philips N.V. (US), Roche Diagnostics (US), Abbott (US), Alere (US), Sorin Group (Italy), BIOTRONIK SE & Co. KG (Germany), Bio-AMD (UK) and others.